GlassScriptPhysician profile
John D Kilgallin
NPI 1881679496
$1,100.21
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $372 · 2020: $308 · 2021: $359 · 2022: $60.73.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $135.01 | 2019-2020 | |
| Abbvie INC. | $112.55 | 2021 | |
| Novartis Pharmaceuticals Corporation | $92.22 | 2019-2022 | |
| Amgen INC. | $81.55 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $80.93 | 2020-2021 | |
| Novo Nordisk INC | $73.77 | 2019-2021 | |
| Pfizer INC. | $65.17 | 2019 | |
| Lilly USA, LLC | $58.60 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $51.56 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $49.30 | 2019-2021 | |
| Allergan, INC. | $37.82 | 2019-2020 | |
| Amarin Pharma, INC. | $37.53 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $35.54 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $33.05 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $30.82 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amryt Pharma Holdings LTD | $18.55 | 2021 | |
| Seqirus USA INC | $18.51 | 2021 | |
| Astellas Pharma US INC | $17.61 | 2019 | |
| Dexcom, INC. | $15.32 | 2021 | |
| Gilead Sciences, INC. | $15.32 | 2019 | |
| Genentech USA, INC. | $13.76 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.90 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.82 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kilgallin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.